Gonorrhoea has been identified as one of three urgent threats by the US Centers for Disease Control and Prevention (‘CDC’) and a high priority pathogen by the World Health Organisation. It is estimated by the WHO that there are approximately 106 million new cases of gonorrhoea globally per year. The US CDC reported in 2013 that 30% of new cases are resistant to at least one of the antibiotics currently used to treat gonorrhoea. Further the organism responsible for this infectious disease, Neisseria gonorrhoea, has consistently developed resistance to each class of antibiotics recommended for treatment. In 2006 the CDC recommended five treatment options. There is now only one, a combination of two antibiotics. There are currently no other antibiotics that can be effectively deployed to target the disease.
Novel Mechanism Antibiotics for Gonorrhoea
Through our proprietary bacterial genetics platform, a new series of antibiotics has been identified that can kill gonorrhoea via new mechanisms of action. In early-testing, this series of antibiotics has been shown to have high potency against gonorrhoea bacteria with no development of resistance to date. We believe the identified series of antibiotics have the potential to produce a new front-line therapy for gonorrhoea. We intend to select a candidate from the gonorrhoea programme for progression into IND enabling studies in the second half of 2018.